Concanavalin A Clinical Trials

Size	Price	Qty
5mg	USD 147

Clinical Trials

A clinical trial has evaluated the clinical application of this compound through a completed Phase I study assessing immunomodulatory responses and clinical progress in pediatric pneumonia patients. Sponsored by academic and healthcare institutions including the Universidad Nacional Autonoma de Mexico, Hospital General de Mexico, and Hospital Pediatrico de Coyoacan, this trial provides foundational human data regarding the compound's capacity to modulate immune functions during acute respiratory infection.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03690583	Completed	Pneumonia\|Children Only	Universidad Nacional Autonoma de Mexico\|Hospital General de Mexico\|Hospital Pediatrico de Coyoacan	2014-01-29	Phase 1

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Concanavalin A product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Concanavalin A selectively binds to cell-surface carbohydrate residues, thereby triggering downstream signaling pathways that induce apoptosis, regulate autophagy, and inhibit cell survival mechanisms. This targeted modulation of cellular signaling and immune responses provides the mechanistic rationale for evaluating its therapeutic potential in clinical conditions such as pediatric pneumonia.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).